Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatment.

ABSTRACT: Biliary tract cancers are rare cancers with poor prognosis due to a lack of therapeutic options, especially after the failure of first-line systemic treatment. Targeted treatments for this clinical situation are promising and have entered clinical practice. We aimed to describe the overall survival of matched targeted treatment after first-line treatment in patients with biliary tract cancers in an Austrian real-world multicenter cohort. We performed a multicenter retrospective chart review of patients with biliary tract cancer between September 2015 and January 2022. Data, including comprehensive molecular characteristics-next generation sequencing (NGS) and immunohistochemistry (IHC), clinical history, surgical procedures, ablative treatments, patient history, and systemic chemotherapy,

SUBMITTER: Doleschal B 

PROVIDER: S-EPMC10507096 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature